IP Library Granted Patent US 9,790,518
Granted Patent B2
US 9,790,518 · App. 14/815,721 · Granted Oct 17, 2017

Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine

Inventors: John J. Nemunaitis (Cedar Hill, TX); Neil Senzer (Dallas, TX); Phillip B. Maples (Pilot Point, TX); Donald Rao (Dallas, TX)
Assignee: GRADALIS, INC.
C12N15/85A61K31/7088A61K31/7105A61K35/13A61K38/217A61K39/0011
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,790,518
App. No.
14/815,721
Granted
Oct 17, 2017
Kind
B2
Abstract

Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to segment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.

Claims (15)

1. A method of treating a cancer in an individual in need thereof comprising:

a. transfecting an autologous tumor cell from the individual with an expression vector comprising:

i. a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence; and

ii. a second insert comprising a sequence according to SEQ ID NO: 2; and

b. administering the transfected tumor cell to the individual.

2. The method of claim 1 , wherein the GM-CSF is a human GM-CSF sequence.

3. The method of claim 1 , wherein the expression vector further comprises a promoter.

4. The method of claim 3 , wherein the promoter is a cytomegalovirus (CMV) mammalian promoter.

5. The method of claim 4 , wherein the expression vector further comprises a CMV enhancer sequence and a CMV intron sequence.

6. The method of claim 3 , wherein the first insert and the second insert are operably linked to the promoter.

7. The method of claim 1 , wherein the expression vector further comprises a nucleic acid sequence encoding a picornaviral 2A ribosomal skip peptide between the first and the second nucleic acid inserts.

8. The method of claim 1 , wherein the cancer is a melanoma, non-small cell lung cancer (NSCLC), gall bladder cancer, colorectal cancer, breast cancer, ovarian cancer, liver cancer, liver cancer metastases, or Ewing's sarcoma.

9. The method of claim 1 , wherein the transfected tumor cell is administered to the individual as a dose of about 1×10 7 cells to about 5×10 7 cells.

10. The method of claim 9 , wherein the transfected tumor cells are administered to the individual once a month.

11. The method of claim 1 , wherein the transfected tumor cell is administered to the individual by intradermal injection.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Dec 20, 2019
From: GRADALIS, INC.
To: HC INNOVATIVE PARTNERS, LP, AS COLLATERAL AGENT
Reel/Frame 051396/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2015
From: NEMUNAITIS, JOHN J.; SENZER, NEIL; MAPLES, PHILLIP B.; RAO, DONALD
To: GRADALIS, INC.
Reel/Frame 036405/0835 →
Continuity (4)
Continuation 12973823 · Dec 20, 2010
Provisional Application 61289681 · Dec 23, 2009
Provisional Application 61309777 · Mar 2, 2010
Related Publication 20150329873A1 · Nov 19, 2015